首页> 外文OA文献 >Human soluble epoxide hydrolase: Structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids
【2h】

Human soluble epoxide hydrolase: Structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids

机译:人可溶性环氧水解酶:4-(3-环己基脲基)-羧酸抑制的结构基础

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

X-ray crystal structures of human soluble epoxide hydrolase (sEH) complexed with four different dialkylurea inhibitors bearing pendant carboxylate “tails” of varying length have been determined at 2.3–3.0 Å resolution. Similarities among inhibitor binding modes reinforce the proposed roles of Y381 and/or Y465 as general acids that protonate the epoxide ring of the substrate in concert with nucleophilic attack of D333 at the electrophilic epoxide carbon. Additionally, the binding of these inhibitors allows us to model the binding mode of the endogenous substrate 14,15-epoxyeicosatrienoic acid. Contrasts among inhibitor binding modes include opposite orientations of inhibitor binding in the active-site hydrophobic tunnel. Alternative binding orientations observed for this series of inhibitors to human sEH, as well as the binding of certain dialkylurea inhibitors to human sEH and murine sEH, complicate the structure-based design of human sEH inhibitors with potential pharmaceutical applications in the treatment of hypertension. Thus, with regard to the optimization of inhibitor designs targeting human sEH, it is critical that human sEH and not murine sEH be utilized for inhibitor screening, and it is critical that structures of human sEH-inhibitor complexes be determined to verify inhibitor binding orientations that correlate with measured affinities.
机译:已确定人类可溶性环氧化物水解酶(sEH)与四种不同的带有不同长度的侧链羧酸“尾部”的二烷基脲抑制剂复合的X射线晶体结构,分辨率为2.3–3.0Å。抑制剂结合模式之间的相似性加强了Y381和/或Y465作为一般酸的拟议作用,该一般酸与D333在亲电子环氧化物碳上的亲核攻击协同作用,使底物的环氧化物环质子化。此外,这些抑制剂的结合使我们能够模拟内源性底物14,15-环氧二十碳三烯酸的结合模式。抑制剂结合模式之间的对比包括活性位点疏水通道中抑制剂结合的相反方向。在这一系列抑制剂与人sEH上观察到的替代结合方向以及某些二烷基脲抑制剂与人sEH和鼠类sEH的结合使人sEH抑制剂的基于结构的设计复杂化,在治疗高血压方面具有潜在的药物应用。因此,关于针对人sEH的抑制剂设计的优化,关键是将人sEH而不是鼠用sEH用于抑制剂筛选,并且至关重要的是确定人sEH-抑制剂复合物的结构以验证抑制剂的结合方向。与测得的亲和力相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号